Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,767 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07186452RecruitingPhase 1
Testing HS-20093 with itraconazole in advanced solid tumors
This trial checks if a drug called itraconazole affects how your body processes another drug, HS-20093. It is for people with advanced solid tumors who have tried standard treatments or cannot tolerate them.
Changsha, HunanAges 18 years+ - NCT07192107RecruitingPhase 1/Phase 2
Study of MHB042C for advanced solid tumors
This trial tests a new drug called MHB042C for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT06669975RecruitingPhase 1/Phase 2
Testing AP402 for her2-positive advanced solid tumors
This trial tests an experimental drug called AP402 for people with HER2-positive solid tumors that have spread or cannot be removed by surgery, and who have no standard treatment options left. The goal is to see if AP402 can shrink tumors or slow their growth.
Macquarie, New South WalesAges 18 years+ - NCT07177937RecruitingPhase 1
Study of DXC014 for advanced solid tumors
This trial tests DXC014, a new drug, in people with advanced solid tumors, including prostate cancer. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07182591RecruitingPhase 1
Study of DS5361b for advanced solid tumors with high TMB or MSI
This study tests a new drug (DS5361b) for people with advanced solid tumors that have high genetic instability (TMB-H or MSI-H). It aims to see if the drug can shrink tumors or slow their growth.
Sarasota, FloridaAges 18 years+ - NCT07166601RecruitingPhase 1
Study of a drug for advanced solid tumors with MUC-1 marker
This trial tests a new drug, M0324, alone or combined with pembrolizumab or chemotherapy, for advanced solid tumors that have a protein called MUC-1 on their surface. It may be an option for patients whose cancer has not responded to standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT06497010RecruitingEarly Phase 1
Personalized mRNA cancer vaccine for advanced solid tumors
This trial tests a personalized mRNA vaccine (InnoPCV) designed from your own tumor's genetic profile to train your immune system to fight advanced solid tumors. It is for people who have not had tumor vaccines or CAR-T therapy before and can provide a tumor sample for customized vaccine creation.
Guiyang, China/GuizhouAges 18–75 - NCT06954558RecruitingPhase 1
GK01 for advanced solid tumors that are hard to treat
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
TianjinAges 18–70 - NCT07161414RecruitingPhase 1
Study of rilvegostomig for advanced solid tumors
This study tests a new investigational drug, rilvegostomig, given as an injection under the skin. It is for people with advanced solid tumors that have not responded to or have progressed after standard treatments. The goal is to see how the drug behaves in the body and to assess its safety.
Huntersville, North CarolinaAges 18 years+ - NCT07163325RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new oral drug called EP102 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug is safe and works by targeting a protein called METTL3.
BrusselsAges 18 years+ - NCT05263960RecruitingPhase 1/Phase 2
CM350 drug study for advanced solid tumors
This trial tests CM350 in people with advanced solid cancers that are hard to treat with standard options. It may help by finding a safe dose and whether the drug can work against these cancers.
Chengdu, SichuanAges 18–75 - NCT07147348RecruitingPhase 1/Phase 2
BNT3212 alone or with BNT327 for advanced solid tumors
This trial tests a new drug called BNT3212, either alone or combined with BNT327, in people with advanced solid tumors that have not gotten better with standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow their growth.
AdelaideAges 18 years+ - NCT06304571RecruitingPhase 1
Study of HC006 for advanced solid tumors
This study tests a new drug called HC006 for advanced solid tumors that no longer respond to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07136779RecruitingPhase 1/Phase 2
Study of VBC101 for advanced solid tumors
This trial tests a new drug called VBC101 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if VBC101 is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT07142980RecruitingPhase 1
Study of HRS-7172 for advanced solid tumors with RAS mutations
This trial tests a new drug, HRS-7172, for people with advanced solid tumors that have RAS mutations or amplifications. It aims to see if the drug is safe and effective for these cancers.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07139067RecruitingPhase 1
YK1101 for advanced solid tumors
This trial tests a new cell therapy called YK1101 for people with advanced solid tumors that have not responded to standard treatment. It targets a specific protein (MAGE-A4) on cancer cells and requires a matching genetic type called HLA-A*11:01.
BeijingAges 18–75 - NCT07131202RecruitingPhase 1/Phase 2
FL115 plus PD-1 antibody for advanced solid tumors
This trial tests a new drug called FL115 combined with an immunotherapy (PD-1 antibody) for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if this combination can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18–80 - NCT07126665RecruitingPhase 1/Phase 2
Study of MHB088C plus MHB039A for advanced solid tumors
This trial tests a combination of two experimental drugs, MHB088C and MHB039A, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07134998RecruitingPhase 1
Study of HRS-6093 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07135128RecruitingPhase 1
Study of a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.
Jinan, ShandongAges 18 years+ - NCT07124117RecruitingPhase 1/Phase 2
Study of OBI-902 for advanced solid tumors
This trial tests an experimental drug called OBI-902 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if OBI-902 can help shrink or control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT07107230RecruitingPhase 1
Study of JNJ-95437446 for advanced solid tumors
This trial tests a new drug, JNJ-95437446, in people with certain advanced cancers (non-small cell lung, colorectal, or head and neck cancer). The goal is to see if it can help shrink or control the cancer.
Sarasota, FloridaAges 18 years+ - NCT07110883RecruitingPhase 1
Study of SYS6023 for advanced solid tumors
This trial tests a new drug called SYS6023 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if your tumor has a specific protein called HER3 or certain genetic changes.
Harbin, HeilongjiangAges 18 years+ - NCT07108114RecruitingPhase 1
SLV-324 for advanced solid tumors that have spread
This phase 1 trial tests a new drug called SLV-324 for people with solid tumors that have spread and are no longer responding to standard treatments. The goal is to see if the drug is safe and works against the cancer.
Newport Beach, CaliforniaAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,767 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.